|
|
|
|
|
|
|
14.04.26 - 12:24
|
MSD, Daiichi Sankyo′s ifinatamab deruxtecan receives FDA priority (PBR)
|
|
|
The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026
The post MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
14.04.26 - 12:24
|
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook (Business Wire)
|
|
|
2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%*
2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70
Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint
Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients
Company announces planned Enterprise Business Review for December 8, 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Jo...
|
|
|
14.04.26 - 12:24
|
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% (Business Wire)
|
|
|
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases.
At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, ...
|
|
|
14.04.26 - 12:21
|
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings (Benzinga)
|
|
|
Abbott Laboratories (NYSE: ABT) to report Q1 earnings on April 16, expected EPS of $1.15 and revenue of $11B. Acquired Exact Sciences, stock up 0.4%.
Latest Ratings for ABT
DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Jan 2022Raymond JamesMaintainsOutperform Jan 2022Morgan StanleyMaintainsOverweight
View More Analyst Ratings for ABT
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
14.04.26 - 11:30
|
Novo Nordisk Partners with OpenAI to Accelerate Drug Development (AAStocks)
|
|
|
Novo Nordisk, the Denmark-based manufacturer of the so-called "weight-loss miracle drug", said on Tuesday (14th) that it will collaborate with US AI startup OpenAI to deploy artificial intelligence across various aspects of its operations, ranging from drug discovery to manufacturing and commercial operations.Novo Nordisk stated......
|
|
|
|
|
14.04.26 - 11:00
|
GSK Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Hold" belassen. Dies schrieb Emmanuel Papadakis in einem am Dienstag vorliegenden Kommentar zu einer Analystenkonferenz nach den Daten ......
|
|
|
14.04.26 - 10:48
|
Aktie "falsch bewertet": Wie Evotec am KI-Boom verdient (Ariva)
|
|
|
KI macht Arzneimittelforschung billiger ? und schafft paradoxerweise mehr Arbeit für Evotec. Warum Berenberg die Aktie trotz operativer Schwäche klar zum Kauf empfiehlt. Die Pharmaindustrie setzt zunehmend auf künstliche Intelligenz, um neue Wirkstoffe schneller und günstiger zu entwickeln – und genau das könnte für Evotec zum Wachstumstreiber werden. Ausgerechnet KI-getriebene Pharmafirmen fragen verstärkt nach den Labordiensten des ......
|
|
|
14.04.26 - 10:48
|
JPMorgan bringt Berichtssaison in Schwung (MarktEinblicke)
|
|
|
Am Dienstag werden Anleger ganz besonders auf die Zahlen bei BlackRock, Citigroup, Johnson & Johnson, JPMorgan Chase und Wells Fargo schauen.
The post JPMorgan bringt Berichtssaison in Schwung first appeared on marktEINBLICKE....
|
|
|
14.04.26 - 10:45
|
Evotec-Aktie: Strohfeuer oder nachhaltiger Ausbruch? (Sharedeals)
|
|
|
Die Aktie des Hamburger Wirkstoffforschers hat im Zuge einiger positiver News zuletzt wieder an Momentum gewonnen. Mehrere Analysten sehen deutliches Aufwärtspotenzial, nachdem sich der Kurs zuvor auf sehr niedrigen Niveaus stabilisieren musste. Gleichzeitig bleibt das Bild jedoch ambivalent: Strukturelle Zweifel an der mittelfristigen Entwicklung sind noch nicht vollständig ausgeräumt. Die Aktie von Evotec hat nach […]
The post Evotec-Aktie: Strohfeuer oder nachhaltiger Ausbruch? first appeared on sharedeals.de....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
